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Abstract: Glioblastoma (WHO grade IV glioma) is the most common malignant primary brain tumor
in adults. Survival has remained largely static for decades, despite significant efforts to develop new
effective therapies. Immunotherapy and especially immune checkpoint inhibitors and programmed cell
death (PD)-1/PD-L1 inhibitors have transformed the landscape of cancer treatment and improved patient
survival in a number of different cancer types. With the exception of few select cases (e.g., patients with
Lynch syndrome) the neuro-oncology community is still awaiting evidence that PD-1 blockade can lead
to meaningful clinical benefit in glioblastoma. This lack of progress in the field is likely to be due
to multiple reasons, including inherent challenges in brain tumor drug development, the blood-brain
barrier, the unique immune environment in the brain, the impact of corticosteroids, as well as inter- and
intratumoral heterogeneity. Here we critically review the clinical literature, address the unique aspects
of glioma immunobiology and potential immunobiological barriers to progress, and contextualize new
approaches to increase the efficacy of PD-1/PD-L1 inhibitors in glioblastoma that may identify gaps
and testable relevant hypotheses for future basic and clinical research and to provide a novel perspective
to further stimulate preclinical and clinical research to ultimately help patients with glioma, including
glioblastoma, which is arguably one of the greatest areas of unmet need in cancer. Moving forward,
we need to build on our existing knowledge by conducting further fundamental glioma immunobiology
research in parallel with innovative and methodologically sound clinical trials.
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Glioblastoma (WHO grade IV glioma) is the most common malignant primary brain tumor in 
adults. Survival has remained largely static for decades, despite significant efforts to develop 
new effective therapies. Immunotherapy, and especially immune checkpoint inhibitors and 
programmed death (PD)-1/PD-L1 inhibitors have transformed the landscape of cancer treatment 
and improved patient survival in a number of different cancer types. With the exception of few 
select cases (e.g., patients with Lynch syndrome) the neuro-oncology community is still awaiting 
evidence that PD-1 blockade can lead to meaningful clinical benefit in glioblastoma. This lack of 
progress in the field is likely to be due to multiple reasons, including inherent challenges in brain 
tumor drug development, the blood-brain barrier, the unique immune environment in the brain, 
the impact of corticosteroids, as well as inter- and intra-tumoral heterogeneity. 
Here we critically review the clinical literature, address the unique aspects of glioma 
immunobiology and potential immunobiological barriers to progress, and contextualize new 
approaches to increase the efficacy of PD-1/PD-L1 inhibitors in glioblastoma that may further 
stimulate pre-clinical and clinical research to ultimately help patients with glioma, including 
glioblastoma, arguably one of the greatest areas of unmet need in cancer. Moving forward, we 
need to build on our existing knowledge by conducting further fundamental glioma 





Glioblastoma (GBM; grade IV glioma) is the most common and aggressive type of malignant 
primary brain tumor. The standard of care for glioblastoma, maximal safe surgical resection 
followed by radiotherapy plus temozolomide and adjuvant temozolomide, achieves a median 
overall survival of 15 months 1-3. Despite recent advances in multi-modality therapy for 
glioblastoma, incorporating surgery, radiotherapy, systemic therapy, tumor treating fields, and 
supportive care, median survival remains static at about 15 months, and long-term survival is 
rare 1. Two of three patients have an unmethylated O6-methylguanine-DNA methyltransferase 
(MGMT) promotor that renders them less likely to benefit from DNA alkylating agents such as 
temozolomide or nitrosoureas, and their median survival is even shorter, at about 12 months 4. 
Cancer escapes immunosurveillance via several mechanisms, including activation of immune 
checkpoint pathways that suppress anti-tumor immune responses. Immune checkpoint 
inhibitors reinstitute the immune response by disrupting co-inhibitory signaling pathways aiming 
to eliminate tumor cells. Immune checkpoint blockade has transformed the landscape in several 
cancers, including cancers with brain metastases 5. The main immune checkpoints that have 
been successfully targeted with monoclonal antibodies are programmed death-1 (PD-1),  PD-
ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4). Immunotherapy, especially 
with PD-1/PD-L1 inhibitors, has transformed the management of many cancers, and 
consequently there has been considerable investigation and research into immune-based 
therapeutic approaches for glioma, and specifically GBM. However, to date these therapies 
have not demonstrated a major benefit for these patients. Here, we critically appraise the 
preclinical and clinical literature to provide a novel perspective on how to make progress in this 
area of unmet need. 
Clinical Trials Targeting PD-1/PD-L1 in GBM 
Several phase I/II trials in recurrent and newly diagnosed glioblastoma are evaluating the anti-
PD-1 agents nivolumab, pembrolizumab, cemiplimab or the anti-PD-L1 antibodies 
atezolizumab, avelumab, durvalumab, and other PD-1/PD-L1 inhibitors alone or in combination 
with other therapies. 
Combinations with standard treatment are often developed to test specific synergy hypotheses, 
such as simultaneous PD-1-inhibition and anti-angiogenic therapy (bevacizumab) and/or 
radiotherapy. Examples of this approach include a phase II trial evaluating the anti-PD-L1 
 5 
antibody durvalumab in five different cohorts of patients 6, including combinations with 
radiotherapy for newly diagnosed glioblastoma or with bevacizumab for recurrent glioblastoma. 
Numerous studies of immune checkpoint inhibitors, in newly diagnosed and recurrent 
glioblastoma are ongoing (Table 1) and several studies including phase III studies with 
nivolumab have been reported (Table 2). None of these studies reported findings that could lead 
to approval of these agents.  
Trials have also been conducted with neoadjuvant (pre-operative) administration of PD-1 
inhibitors to induce a more pronounced immune response than with the usual post-resection 
approach (Table 3). In addition to the effect of perioperative corticosteroid administration, 
surgery itself may dampen the immune response, with suppression of cellular immunity as one 
of the host responses to surgical stress7. 
In summary, the phase II and III studies in GBM with nivolumab have not demonstrated a 
meaningful benefit. No other phase III studies with PD-1/PD-L1 inhibitors are planned or have 
been conducted. 
Why are PD-1/PD-L1 Inhibitors Ineffective in GBM? 
Challenges with pre-clinical and clinical trial design paradigms 
Evaluating immunotherapy relies on pre-clinical models to identify targets, conduct mechanistic 
studies, and to optimize delivery and pharmacokinetic aspects. These models have helped 
develop the CTLA-4 and PD-L1/PD-1 inhibitors 8,9. GBM immune biology may not be well 
reflected in the models that are frequently utilized. A commonly used animal model is the GL261 
glioma, which is moderately immunogenic and expresses clonotypic, homogeneous, and robust 
levels of PD-L1, which is not the case human gliomas 10. Pre-clinical models are developed by 
implanting cancer cell lines either in the flank or in the brain of mice. Tumors that are 
successfully implanted rarely represent the GBM immune complexity seen in humans. Common 
pre-clinical models are relatively easy to evaluate as subcutaneous implants. Mice can be 
engineered to approximate, but not completely represent, human GBM. Knocking out 
suppressor genes or induction of somatic mutations can result in de novo tumors, but they do 
not fully represent the accumulation of genetic aberrations that develop in human GBM. The 
immune system is dependent on the tumor microenvironment (TME), which is challenging to 
reproduce in animal models.  
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Humanized mice models using both tumor and immune systems that are patient-specific are an 
improvement to study immunotherapies but they are limited by cost, low engraftment rates and 
slow tumor growth.  
The scarcity of representative pre-clinical models has led to the initiation of clinical trials 
evaluating immunotherapies that have shown promise in other cancers without definitive pre-
clinical rationale in GBM. Clinical trials are often initiated with uncontrolled, open label 
(unblinded), non-randomized, small sample size trials that have inherent selection and other 
biases. This in turn will have a high type I error rate, with ineffective therapies showing false 
positive results that may surreptitiously build the case to start larger studies. Large studies 
minimize risk of bias and false positive results will be less likely to be reproduced. Unfortunately, 
the true effect size or lack of activity only becomes apparent after hundreds of patients have 
participated and millions of research dollars have been invested over the course of several 
years.  
Another factor making interpretation of preclinical findings difficult is that there is never a 
surgical resection of a mouse engrafted with syngeneic glioma cells, which does not recapitulate 
the large number of GBM patients that undergo surgical resection and are enrolled in clinical 
trials evaluating PD-1 inhibitors.  
Zhai et al, demonstrate the use of humanized mice partially reconstituted with a human immune 
system and intracranially-engrafted with human glioblastoma. The authors demonstrate that the 
tumor-infiltrating T cells increase immunosuppression in glioblastoma. The take home message 
from this preclinical study is that it is not sufficient to simply enhance T cell infiltration, but if 
successful, one must then deal with the consequence of the T cell-dependent increase of 
glioblastoma-induced immune suppression.  
 
There are other barriers to translating pre-clinical ideas to human trials. For example, immune 
priming, activation, and memory responses may require sequencing of therapies that are 
challenging to evaluate using the traditional clinical trial paradigms. Another challenge in 
glioblastoma is the inability to collect biopsies at different time-points as it is usually done in 
other solid tumors (at baseline before the immunotherapy, after a few weeks of treatment, and 
often at recurrence). This is one of the differences in glioma drug development as compared 
with other cancers.  
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Challenges with immunotherapy combination studies 
Trials need rational combinations backed by plausible pre-clinically tested hypotheses. 
Integration of pre-clinical and clinical studies to evaluate promising therapies in pre-clinical 
models with a “bench to bedside and back to bench” approach may detect early signals or 
declare ineffective combinations in a more rational manner. Combinations, which may include a 
therapy that has single-agent activity, are challenging to assess in phase I trials due to factors 
such as patient heterogeneity, selection bias, and lack of randomization. Newer methods of 
drug development such as randomization into phase I trials may need to be explored 11,12. 
Unlike chemotherapy, effective combination immunotherapies may include agents that are 
unlikely to independently induce a radiologic response. These combinations may not require 
individual agent activity. Some of the therapies in the combination may have an effect only by 
sensitizing to a second agent (e.g., the CD40 agonistic antibodies). 
Immunosuppression in GBM 
Patients with GBM are known to have significant deficits in cell-mediated immunity within the 
lymphocyte population, and specifically the CD4 cells. 
Tumor-infiltrating lymphocytes 
Tumors can be defined depending on immune infiltration and are classified as immune desert, 
immune-excluded, and hot tumors, depending on the presence of tumor-infiltrating lymphocytes 
(TILs) in tumor specimens 13. A tumor that is characterized as an immune desert can arise from 
immune ignorance, tolerance, or absence of T-cell priming or activation 13. In some studies, the 
numbers of TILs suggest a positive correlation with better prognosis 14-16. While the presence of 
lymphocytes in a tumor sample may represent immune engagement, these lymphocytes might 
be exhausted in GBM and thus may not yield a favorable immune effect. Subsets of TILs may 
differ, as shown in a study where the level of CD8+ T-cells and tumor grade were inversely 
correlated, while the level of CD4+ T-cells and tumor grade were positively correlated 17. TILs or 
CD8+ T-cell infiltrates have been proposed as a surrogate for the presence of antigen, immune 
activation, and trafficking to the TME. They are positively correlated with response to therapy in 
other tumors, particularly melanoma 18 and lung cancer 19. Their exact role in gliomas requires 
further investigation. 
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T-regulatory cells (Tregs) are a highly diverse and plastic subset of CD4 T-cells and are 
important in immune tolerance. The thymus-derived natural Tregs (nTregs), characterized by 
high constitutive expression of FoxP3, cause contact-dependent cytokine-independent 
immunosuppression through CTLA-4 and PD-L1 pathways 20. 
T-cell exhaustion 
A study of T-cell exhaustion in GBM in TILs and peripheral blood lymphocytes isolated from 21 
patients evaluated multiple immune checkpoint markers, including PD-1, CTLA-4, and TIM-3, 
and reported upregulation of multiple immune checkpoints. The T-cell transcriptional profile 
approximated virus-induced exhaustion 21. Another study that reported reduced absolute CD4 
counts in 20 patients with GBM also observed that the fraction containing 
CD4+CD25+FoxP3+CD45RO+ T-cells was increased compared to healthy controls 22. T-cells 
from these patients demonstrated anergy or secreted Th2 polarizing cytokines on stimulation. 
Removal of the Treg population reversed this cytokine signature. Treg removal eliminated T-cell 
proliferative defects and restored TH2 cytokine shifts, where T-cells from patients with 
glioblastoma could function in vitro at levels equivalent to those of healthy controls. 
Another group used glioma samples to demonstrate that the nTreg population is predominant in 
glioma with high FoxP3 expression 23. Thymectomy appeared to help reduce Treg levels in the 
GL261 mouse cell line injected intracranially 24. An analogous approach to restore T-cell 
function is currently being explored in a trial of lymphodepletion in combination with PD-1 
inhibition (NCT02664363) 25. 
One study found no correlation with levels of Tregs and prognosis, suggesting that gliomas may 
also mediate immunosuppression though other mechanisms 26. Some cancers employ loss or 
downregulation of class I MHC to evade immune destruction 27. PD-L1/PD-1 inhibitor activity 
enables an endogenous immune response that relies on previously primed CD8+ T-cells that 
specifically recognize cancer cells. These immune cells can either be re-invigorated or 
expanded by PD-L1/PD-1 inhibition, leading to recognition and targeting of cancer 28. 
Immune desert tumors 
Immune desert cancers like GBM, hormone receptor positive breast cancer, and prostate 
cancer respond poorly to immune checkpoint inhibitors 29-31 for a number of potential reasons, 
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including lack of immune infiltration and impaired antigen presentation (low MHC class I) and 
may have high tumor cell proliferation. 
Distinct mechanisms associated with the immune desert tumors include tumor-intrinsic WNT/β-
catenin signaling that may reduce the chemokine gradient required for recruiting CD103+ 
dendritic cells (including CXCL1, CXCL2, and CCL4) 32. This impacts early T-cell priming and 
infiltration into the TME. Rapidly proliferating immune desert tumors alter the metabolic 
conditions in the TME to create a hostile environment for the function and proliferation of T-cells 
33. T-cells depend on similar glycolytic pathways as tumor cells for survival 34. Lactate 
production, presence of an acidic TME, and lipogenesis may alter the immunometabolism of T-
cells, affecting TCR engagement, T effector activation, differentiation, and proliferation, 
ultimately resulting in reduction or absence of TILs 33. 
Immune ignorance is also associated with the presence of a stem cell-like phenotype in tumors 
(“stemness”) 35. Stemness correlates with higher intratumoral heterogeneity, possibly by 
protecting antigenic clones from elimination by the immune system. Stemness is associated 
with cell intrinsic suppression of endogenous retroviruses, type I interferon signaling, and 
increased expression of multiple immunosuppressive pathways, and may provide a mechanistic 
link between antigenicity, intratumoral heterogeneity, and immune suppression across cancers. 
The TGF-β pathway 
The transforming growth factor-β (TGF-β) pathway is known to be a driver of glioma 
tumorigenicity and immunosuppression. TGF-β secretion is also one of the characteristics of 
immune desert tumors, in addition to lack of TILs and the presence of myeloid-derived 
suppressor cells and VEGF-associated tumor angiogenesis 36,37. The first description of TGF-β 
isoform 2 was as a glioblastoma-derived T-cell suppressor factor, measured in GBM cell lines 
and patient serum 38. TGFβ was noted to suppress T-cell proliferation through IL-2-dependent 
and independent pathways. The TGF-β receptor is highly expressed on glioma cells and RNA 
silencing of TGF-β reduces glioma proliferation, migration, and invasiveness. A clinical trial 
(n=150) that treated GBM patients with lomustine with or without galunisertib, a TGF-β receptor 
inhibitor, failed to demonstrate improved overall survival relative to placebo 39. New approaches 
to targetting TGF-β together with PD-L1 are ongoing 40. 
The immunosuppressive effect of corticosteroids 
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GBM patients typically receive systemic corticosteroid therapy immediately before and after a 
craniotomy. Steroids modulate the immune system, causing lymphopenia, including reducing 
the absolute number of T-cells 41. Corticosteroids are also routinely used to control vasogenic 
edema in gliomas, as well as for the treatment of a variety of autoimmune diseases, immune-
related adverse events triggered by checkpoint inhibition, or cytokine release syndrome. It is 
very common for GBM patient to have received, or to continue to receive, relatively high doses 
of corticosteroids, which may diminish T-cell activity, including that associated with immune 
checkpoint inhibitors. 
There are data to support the hypothesis that systemic corticosteroids used to treat immune-
related adverse events may not compromise the therapeutic benefit of immune checkpoint 
inhibitor therapy 42. However, it is challenging to ascertain whether benefit was achieved before 
or after steroids were given. Individuals who develop immune-related adverse events may have 
more engaged immune systems 43. This creates an inherent bias, especially in retrospective 
analyses. Assessment of the impact of steroids on immunotherapy will also need to take the 
timing of steroid administration into account. While corticosteroids may not completely remove 
the anti-cancer immune response, they can potentially attenuate it. This might be acceptable in 
an immune dominant tumor environment (such as melanoma), but this effect may be more 
significant in immune desert tumors such as GBM. 
Other unclear aspects include the effects of the type, timing, and overall dose of corticosteroids 
on response to immunotherapies. These questions are important but difficult to answer in 
clinical trials. 
Macrophages, Microglia and Myeloid-Derived Suppressor Cells (MDSCs) 
Microglia and non-parenchymal macrophages in the brain are mononuclear phagocytes that are 
increasingly recognized to be important in diseases of the brain. Peripheral immune cells can 
infiltrate the CNS in certain conditions, but microglial precursors migrate to and reside in the 
brain parenchyma. Brain resident macrophages and microglia are essential part of the innate 
immune system against various insults. Parenchymal microglial cells and recruited monocyte-
derived macrophages from the periphery exhibit disease-specific phenotypic characteristics and 
are subpopulations based on their molecular signatures. An abundance of myeloid over 
lymphoid lineage cells during CNS pathology, including gliomas, is a feature of brain immunity 
as compared to extra-CNS immunity44.  
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Macrophages can be divided into M1 type and M2 type macrophages: M1-type macrophages 
have anti-tumor features and secrete pro-inflammatory factors such as IL-6, IL-8 and TNF-α, 
whereas M2-type macrophages have tumor-promoting features and secrete anti-inflammatory 
factors such as IL-10 and TGF-β, promoting tumor cell growth and migration45.  
MDSCs play a major role on tumor microenvironment immunosuppression in blood and tumors 
from glioblastoma patients. MDSC subsets differentially drive immune suppression in a sex-
specific manner. monocytic (mMDSC) versus granulocytic (gMDSC) subsets have different 
contributions46. A mouse study showed that mMDSCs were enriched in the male tumors, while 
gMDSCs were elevated in blood of females46. Only female mice had extended survival with 
depletion of gMDSCs46. mMDSCs could be targeted with anti-proliferative agents in male 
preclinical models, while IL-1b blockade in females inhibit the gMDSC function. In this study, 
patient data showed that proliferating mMDSCs were predominant in male tumors. A high 
gMDSC/IL-1b gene signature correlated with worse prognosis of the female patients.  
PD-L1 is expressed not only by glioblastoma cells but also detected inextracellular vesicles 
(EVs). GBM EV-mediate immunosuppression, by inducing immunosuppressive monocytes 
rather than inhibition of T-cells47. PD-L1 expression is important for the induction of specific 
immunosuppressive monocyte populations but immunosuppression through EVs are complex 
and not limited to PD-L147.  
A recent study reported that resistance to immune checkpoint blockade that is driven by 
macrophages, is established by CD4 T cell suppression and Treg expansion in the tumor 
microenvironment via the PD-L1/PD-1/CD80 axis. This study also reported heterogeneity of 
response in syngeneic tumors and suggest that targeting PD-L1-expressing tumor-associated 
macrophages might overcome resistance to immune checkpoint blockade. 
There are ongoing efforts to exploit these observations therapeutically, including combinations 






Tumors with high expression of PD-L1 or those with increased tumor-infiltrating immune cells 
might be considered inflamed and theoretically may respond to PD-L1 and PD-1 inhibitors. 
While this true to a degree in melanoma, lung, and some other cancers, it has not been 
demonstrated in gliomas. Tissue testing of PD-L1 expression in general, but also in glioma, has 
been challenging, with various antibodies and techniques employing variable cut points for 
positivity 48. In one study, about 61% of gliomas had at least 1% of tumor cells expressing PD-
L1 10, with 38% of gliomas exhibiting at least 5% PD-L1 expression. PD-1, PD-L1, and TIL 
appear to be positively correlated with tumor grade in all gliomas, and levels of expression are 
higher in GBM 49. In other cancers, responses can be identified in cohorts that do not express 
PD-1 or PD-L1 50. It is also uncertain whether expression of PD-1 and/or PD-L1 on infiltrating 
immune and myeloid cells should be considered 51. 
The capacity to present antigens, such as the expression of MHC class I on the surface of 
tumor cells and an intact HLA, is also essential, but difficult to assess for clinical purposes. 
Expression of the gene encoding PD-L1 increases post transcriptionally in human glioma after 
loss of phosphatase and tensin homolog (PTEN) and activation of the phosphatidylinositol-3-OH 
kinase (PI(3)K) pathway. In one study specimens from glioblastoma patients had levels of PD-
L1 protein that correlated with PTEN loss, and tumor-specific T cells lysed human glioma 
targets expressing wild-type PTEN more effectively than those expressing mutant PTEN. This 
may suggest a mechanism linking loss of the tumor suppressor PTEN with immunoresistance, 




Tumor mutational burden 
In melanoma, there is a positive correlation between the median frequency of somatic mutations 
in tumors and overall response to anti-PD-1 therapies 53. A higher mutational load in tumors 
may result in more tumor antigens, increasing immunogenicity 53. Higher mutational load in 
tumors has also been associated with increased survival and long-term benefit from 
immunotherapy 54. Further, RNA sequencing of lung, ovarian, breast, colorectal, brain, and renal 
cancers has shown that tumor immunogenic mutation load was associated with survival 55. 
Mutational load is thought to be a surrogate marker of neoantigen expression. Recognition of 
neoantigens is a major factor in the activity of immunotherapies 56; and therefore neoantigen 
load may be a useful biomarker to facilitate the development of therapeutic approaches that 
selectively enhance T-cell reactivity and may translate to a higher benefit from checkpoint 
blockade. An increase in mutations as we age is well documented, not only in GBM, but in 
cancer in general 57,58. This trend can only be seen in exome-wide analysis, not in the 
commercial next generation sequencing panels that identify genes that are frequently mutated 
as part of the cancer process 59. To test this hypothesis, a phase II trial is currently randomizing 
102 elderly GBM patients (>65 years) in a 2:1 fashion to short course radiotherapy followed by 
temozolomide with or without nivolumab 60. 
However, techniques and cut points for defining mutational load are not harmonized, so other 
more easily measured indices have been proposed, such as determining mutations in the 
exonuclease domain of polymerase E that lead to hypermutation and neoantigen load 61. 
Individuals with germline Lynch syndrome mismatch repair (MMR) defects have long been 
recognized to be at increased risk of central nervous system (CNS) tumors 62,63. 
Figure 1 
Nonetheless, tumors with very high TMB, of which tumors with microsatellite instability (MSI) 
represent the highest fraction of the TMB continuum, respond favorably to PD blockade and this 
has led to the approval of pembrolizumab in any MSI-high tumors, regardless of the organ of 
origin 64. Indeed, patients with biallelic dMMR in glioblastoma have responded to nivolumab 65. 
A small percentage of newly diagnosed tumors and a larger proportion of tumors during and 
after standard therapy with radiation and alkylating agents may have DNA repair defects of 
various types, including a “hypermutator” phenotype that has also been described in GBM 
specimens with MSH6 mutations 66. Another subset of GBMs with a potential hypermutator 
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phenotype are lower-grade gliomas that recur after treatment with alkylator therapy 67. 
Theoretically, this may make these tumors responsive to immune checkpoint blockade 68.  
Touat et al69 analyzed molecular determinants of mutational burden and signatures in 10,294 
gliomas. Two main pathways to hypermutation were described, one associated with 
constitutional defects in DNA polymerase and mismatch repair (MMR) genes, and a more 
common post-treatment pathway, associated with acquired resistance driven by MMR defects in 
chemotherapy-sensitive gliomas that relapse following temozolomide.  
Experimentally, mutational signature of post-therapy hypermutated gliomas was reintroduced by 
temozolomide-induced damage in cells with MMR deficiency. MMR-deficient gliomas that 
lacked prominent T cell infiltrates had extensive intratumoral heterogeneity, poor patient 
survival, and a low rate of response to PD-1 blockade. Bulk analyses did not detect MSI in 
MMR-deficient gliomas, but single-cell whole-genome sequencing analysis of post-treatment 
hypermutated glioma cells identified microsatellite mutations.  This study shows that 
chemotherapy may introduce hypermutated populations without promoting a response to PD-1 
inhibitors. Touat et al defined high TMB as ≥17.0 mut. per Mb. However, the cutoff for TMB is 
not well defined and response to PD-1 inhibitors in inflamed tumors may differ from that in non-
inflamed tumors 70. Intratumoral heterogeneity may have a greater impact on immune response 
and may predict immunotherapy outcomes better than mutational burden 35. All of these 
complexities make the value of TMB as a biomarker questionable, with respect to highly 
heterogeneous tumors such as GBM, even in those with MMR defects. 
There have been no prospective studies in gliomas, including spontaneously arising gliomas 
without a predisposing germline alteration, which have addressed the associations of mutational 
load and dMMR. Retrospective series have shown disappointing results of patients with high 
TMB but without germline Lynch syndrome or MSI-high status treated with immune checkpoint 
blockers 71. 
Other Biomarkers 
It is possible that PD-1/PD-L1/TMB and others are bystanders and thus not the ideal biomarkers 
in a disease like GBM. Other indicators of immune engagement, such as inflammation markers, 
might be more valuable. One example may be assessment of the role of inflammasomes, which 
are important for CD8+ T-cell activation in response to PD-1 blockade. This can induce a PD-L1-
NLRP3 inflammasome signaling cascade that ultimately may lead to the recruitment of 
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granulocytic myeloid-derived suppressor cells into tumor tissues 72. There may be other (yet 
unknown) and underexplored mechanisms dampening a potential anti-tumor immune response 
in GBM. 
The blood-brain barrier 
The blood-brain barrier (BBB) prevents the passive movement of cells and molecules that could 
induce inflammation or damage to the CNS. Endothelial cells, and the intact tight junctions 
between them, interact to maintain the integrity of the BBB, but do respond to environmental 
changes. Brain pathologies may permit the passage of circulating monocytes and lymphocytes 
from the periphery (57,58). Passage of T-cells across the BBB involves adhesion molecules and 
chemokines that might vary for different immune cell populations; e.g., CD8+ T-cells seem to be 
dependent on α4 integrin 73. 
PD-1 and PD-L1 antibodies are relatively large molecules and may not achieve high 
intratumoral concentrations, which could diminish their therapeutic benefit. However, they may 
not need to cross the BBB if they have a potent systemic immune effect. They may achieve 
some of their goals by acting on T-cells that are circulating or localized within lymphatic 
structures. 
Various invasive and noninvasive approaches have been used for drug and gene delivery into 
the brain parenchyma with or without altering BBB homeostasis 74,75. However, the 
macroscopically normal peritumoral zone is recognized as the primary site of GBM recurrence 76. 
Immune surveillance, antigen presentation, and the role of myeloid cells in the CNS are complex 
and requires lymphatic drainage to lymph nodes 77. Unlike extracranial organs, the brain contains 
a sparse lymphatic network. Cerebrospinal fluid is drained through the meningeal lymphatics into 
the deep cervical lymph nodes where brain-derived antigens and peripheral T-cells interact 78. 
The vascular endothelial growth factor-C (VEGF-C; a growth factor for lymphatic vessels), can 
influence immune interactions via the BBB 79. GL261 mice treated to increase VEGF-C expression 
were able to reject intracranial GBM tumor implants 79. These mice also reject a re-challenge with 
flank tumor implants, demonstrating the generation of memory responses. The survival benefit in 
mice with only intracranial tumors treated with VEGF-C/anti-PD-1 combination therapy was similar 
to that in mice with both intracranial and flank tumors treated with checkpoint inhibitor therapy 
alone. Ligation of the deep cervical lymph nodes abrogated the VEGF-C benefit in mice with 
intracranial tumors, but not mice with both intracranial and flank implants. T-cell priming through 
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expression of VEGF-C in the cerebrospinal fluid, or through a flank tumor, enables checkpoint 
inhibition in the CNS. However, in these experiments, a tumor that was confined to the CNS at 
steady state (e.g., GBM), did not benefit from an immune checkpoint inhibitor alone 79. 
In contrast to GBM, combined anti-PD-1 and anti-CTLA-4 have extracranial and intracranial 
activity in melanoma and lung cancer80. Mice with both a flank and an intracranial tumor respond 
better to combination immunotherapy than those with just intracranial melanoma 81. This may 
mean that immune checkpoint inhibitors are effective intracranially if the relevant immune 
signatures against the tumor are present to induce an extracranial immune response. 
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PD-1 Blockade in GBM: Ongoing Approaches 
While the results of single-agent PD-1 blockade remain unsatisfactory to date, a number of new 
strategies are being considered, including the combination of PD-1 blockade with other immune 
checkpoint inhibitors, as well as targeted agents, radiation therapy, and chemotherapies. 
Combination therapy with two or more therapeutic agents is a cornerstone of cancer therapy. 
There are barriers to the conduct of combination studies. These include toxicity, challenges with 
combination trial design, and the interpretation of endpoints. Endpoints, including the objective 
response rate, progression-free survival, and overall survival, have not evolved to optimally 
assess responses to immunotherapy. Trials are often underpowered and may require prolonged 
follow-up, often lasting multiple years 82. Response assessment does not take into account the 
potential for immune checkpoint inhibitors to lead to either a delayed responses (e.g., continued 
tumor growth followed by tumor shrinkage) or “pseudoprogression” (e.g., apparent tumor growth 
driven by tumor inflammation followed by tumor shrinkage). It is yet to be seen if these issues 
will be addressed by the prospective use and validation of immune-related response criteria 
such as the Immunotherapy Response Assessment in Neuro-Oncology (iRANO) 83. Validation 
requires large datasets and iterative modifications and ultimately may be optimized for the 
immunotherapy setting. 
A number of immunotherapies other than immune checkpoint blockers are currently under 
investigation alone, or in combination with PD-1 blockade. These include viral therapies, cancer 
vaccines, adoptive T-cells, and targeting ubiquitous viral antigens, such as those from 
cytomegalovirus (CMV), as well as therapies that aim to induce broad-based immune 
responses. These approaches may include targeting components of the innate immune system 
through oncolytic viruses, Toll-like receptors, the inflammasome, and other means to generate 
pathogen-associated molecular patterns and/or exploit self-molecules known as damage-
associated molecular patterns to achieve immunogenic cell death 84,85. 
Conclusions 
While there is an urgent unmet need for glioma and GBM clinical research to find therapeutic 
breakthroughs, investment will need to continue in fundamental basic science in order to 
increase our understanding of the immunobiology of gliomas. More pre-clinical novel animal and 
humanized models are needed to better evaluate immune checkpoint inhibitors and combination 
immunotherapies(Table 4). 
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Phase I and phase II trials of PD-1/PD-L1 inhibitors, either alone or in combination, have 
reported safety and also some promising efficacy outcomes, but larger studies with adequate 
statistical power are needed. 
Biomarkers for targeted therapies are usually based on a genetic aberration in the target itself 
(e.g., BRAF mutations, ALK translocations). These are reported clinically as either positive or 
negative assay results. This is different from immune biomarkers, which may need to be 
expressed as a matrix of PD-L1 expression, TMB, and tumor-derived interferon-γ gene 
signatures. While some have suggested developing an immunogram 86 that includes all 
components of the immune system, identification of specific pathway drivers, such as TGFβ, 
myeloid biology, WNT/β-catenin, or altered tumor metabolism requires complex approaches, 
including metabolic, biochemical, cellular and nucleic acid-based assays. 
Capitalizing on the success of PD-1 blockade in other malignancies, new approaches will need 
to build on new insights in glioma immunobiology to develop the next generation of clinical trials 








NCT Number Study Title Phase Size 
(n) 
NCT03426891 Pembrolizumab and Vorinostat Combined With Temozolomide for Newly 
Diagnosed Glioblastoma 
  1 32 
NCT03491683 INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With 
Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma  
  1/ 2 52 
NCT03532295 Epacadostat in Combination With Radiation Therapy and Avelumab in Patients 
With Recurrent Gliomas 
  1/ 2 55 
NCT03665545 Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing 
Glioblastoma 
  1/ 2 24 
NCT02794883 Tremelimumab and Durvalumab in Combination or Alone in Treating Patients 
With Recurrent Malignant Glioma 
  2 36 
NCT03493932 Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma 
Patients Undergoing Checkpoint Blockade 
  1 15 
NCT03661723 Pembrolizumab and Reirradiation in Bevacizumab Naive and Bevacizumab 
Resistant Recurrent Glioblastoma 
  2 60 
NCT03018288 Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without 
HSPPC-96 in Newly Diagnosed Glioblastoma  
  2 108 
NCT03557359 Nivolumab for Recurrent or Progressive IDH Mutant Gliomas   2 37 
NCT03743662 Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT 
Methylated Glioblastoma 
  2 94 
NCT03174197 Atezolizumab in Combination With Temozolomide and Radiation Therapy in 
Treating Patients With Newly Diagnosed Glioblastoma 
  1|/2 60 
NCT03636477 A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in 
Subjects With Glioblastoma; a Substudy to ATI001-102 
  1 18 
NCT03233152 Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of 
Recurrent Glioblastoma 
  1 6 
NCT03722342 TTAC-0001 and Pembrolizumab Combination Trial in Recurrent Glioblastoma   1 20 
NCT03047473 Avelumab in Patients With Newly Diagnosed Glioblastoma    2 30 
NCT03707457 Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients 
With First Recurrence of Glioblastoma 
  1 30 
NCT03718767 Nivolumab in People With IDH-Mutant Gliomas With and Without Hypermutator 
Phenotype 
  2 95 
NCT03341806 Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma   1 30 
NCT04047706 
 
Radiation, nivolumab, and BMS986205 (IDO inhibitor)  1  
NCT03367715 Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly 
Diagnosed, MGMT Unmethylated Glioblastoma 
  2 24 
NCT03673787 A Trial of Ipatasertib in Combination With Atezolizumab   1/ 2 51 
NCT02829931 Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and 
Bevacizumab in Patients With Recurrent High Grade Gliomas 
  1 26 
NCT03291314 Combination of Avelumab and Axitinib for the Treatment of Patients With 
Recurrent Glioblastoma 
  2 52 
NCT03430791 Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for 
Bevacizumab-naive, Recurrent Glioblastoma 






Table 2; Examples of Completed Clinical Trials including PD-1/ PD-L1 inhibitors in gliomas and glioblastoma 
 
NEWLY DIAGNOSED GLIOBLASTOMA TRIALS 








  3 CheckMate-
498 
NCT02617589 
550 patients randomized 
This study confirmed the safety of PD-1 blockade plus 
radiotherapy for newly diagnosed GBM patients, but did 
not demonstrate either an overall survival or 
progression-free survival advantage3 








  3 CheckMate-
548 
NCT02667587 
693 patients randomized 
The study did not demonstrate an improvement in 
progression-free survival, but its overall survival 
findings are pending further maturation of study follow-
up data3 
RECURRENT GLIOBLASTOMA TRIALS 








 369 patients randomized  
 No difference in overall outcome between the 
nivolumab or bevacizumab  
 Median OS was 9.8 months with nivolumab, 10.0 
months with bevacizumab 
 Nivolumab responses were durable (median of 11 
months), similarly to what is seen in other solid tumors 
and much longer than bevacizumab or other 
chemotherapies.  
 No steroid use and MGMT promoter methylation were 
associated with longer OS in the nivolumab arm versus 






16 patients enrolled had received prior chemotherapy, 
and 50% prior bevacizumab.  
Ten patients (63%) experienced a treatment-related 





L1 and TGF-β 
(bintrafusp 
alfa) 40 
IB NCT02517398 35 patients enrolled 
Two patients had a PR, and 9 had SD  
The most common TRAEs were gingival bleeding 
(17.1%), asthenia (14.3%), pruritus, and rash (each 
11.4%).  
Abbreviations: MGMT: O6-methylguanine-DNA methyltransferase, PR: Partial Response, RT: Radiation Therapy, SD: 
Stable Disease, TMZ: Temozolomide, TRAE: Treatment Related Adverse Events,  
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Table 3; Examples of Completed Neoadjuvant Clinical Trials including PD-1/ PD-L1 inhibitors in glioblastoma 
 
NEADJUVANT GLIOBLASTOMA TRIALS 







II NCT02550249 A 30 patient single-arm trial 87.  
An increase in expression of chemokine transcripts, 
higher immune cell infiltration, and augmented T-cell 
receptor clonal diversity among tumor-infiltrating T 
lymphocytes, was reported in patients receiving 








II  35 patient enrolled 
Better survival in the presurgical-surgical PD-1 88, 
together with an upregulation of T-cell and interferon-
γ-related gene expression, but downregulation of cell 
cycle-related gene expression within the tumor. This 
was not seen in the control group. Peripheral markers 
of immune engagement were observed more often in 
the neoadjuvant group than in patients treated only in 




II NCT02337686 15 patients enrolled 
Indirect signs of immune engagement was observed.  
The study concluded that anti-PD-1 monotherapy is 
insufficient for an immunomodulatory response in the 
majority of GBM patients, likely due to paucity of T-
cells within the tumor microenvironment and a CD68+ 




Table 4; Summary of the issues, barriers, recommendations and future directions 
 
Why PD-1 inhibitors were successful in many cancers but not in GBM? The Major Biological Barriers 
 Tumor heterogeneity 
 Drug delivery, blood brain barrier issues and the challenges with obtaining brain biopsies  
 Immunosuppression 
 Lack of neoantigens and low tumor mutational burden 
Challenges in Identifying Reliable Immune Biomarkers in GBM 
 Unless there is a confirmed effective immunotherapy in GBM it will not be possible to validate relevant 
biomarkers. 
 Most biomarkers are discovered in reverse. They may represent association and not causation; i.e., tumor 
mutational burden (TMB) and other usual biomarkers might not have the same relevance in GBM and other 
cancers. 
 Currently used biomarkers for PD-1/PD-L1 inhibitors include PD-L1 expression, TMB, TIL infiltration, and 
immune activation gene expression profiles. 
 PD-L1expression may also change over time. Laboratory evaluation is typically based on archival specimens, 
which may not reflect the phenotype at the time of PD-1 administration. 
 TMB may be a useful predictor in some solid tumors, but it has not been evaluated specifically in GBM. 
 Large sample sizes and large validations sets are required to discover reliable biomarkers. This has been a 
challenge in GBM. 
 There is a need to explore other biomarkers in addition to the traditional PD-L1, TMB, and others that might be 
helpful in other cancers but not in GBM. 
Recommendations and Future Directions 
 Design trials that can answer questions, minimize risk of producing uninterpretable results 
 Minimize use of corticosteroids 
 Develop strategies that can address heterogeneity 
 Encourage neoadjuvant/phase 0/window of opportunity studies 
 Develop more useful biomarkers/T-cell assays, etc. 
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